business
The world is desperate for weight-loss drugs. But Big Pharma can’t advertise them globally
Summary by The El Paso Editorial Desk · Based on reporting by CNN Newsource , KVIA ABC-7
· July 21, 2026
· 7 min read
By Anna Cooban, CNN London (CNN) — The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a $220 billion pharmaceutical company. It was day two of two. In a few hours’ time, the ...
Story provenance No corrections
Summary created by The El Paso Editorial Desk — automated, rule-governed Original reporting CNN Newsource, KVIA ABC-7 Original story Read at the source Source published Jul 21, 2026 Indexed here Jul 21, 2026 AI assistance Automated summary drawn from the source’s own published text Prepublication human review No — editorial rules, flagged-item review, and published samples
Every story comes with a passport. How we work · Corrections log
Key takeaway And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a $220 billion pharmaceutical company.
Why this matters in The El Paso
In El Paso, the lack of direct advertising for prescription weight-loss medications like Ozempic and Wegovy may have a significant impact on public awareness and access to these treatments. While pharmaceutical companies like Novo Nordisk must rely on creative marketing strategies in countries with strict advertising laws, the situation is different in the US. However, El Paso residents may still be exposed to a barrage of advertisements for weight-loss drugs on television and the internet, similar to other American cities. This raises questions about the potential influence of pharmaceutical advertising on healthcare decisions in El Paso, and whether local healthcare providers and patients are adequately informed about the benefits and risks of these medications. As the demand for weight-loss treatments continues to grow, it will be important to monitor how pharmaceutical companies navigate the complex regulatory landscape and how this affects the local healthcare landscape in El Paso.
About this story
Original reporting by KVIA ABC-7 . The El Paso surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit KVIA ABC-7 . Have a tip or correction? Contact our newsroom .
Category: business ·
Published: July 21, 2026 ·
Source: KVIA ABC-7 ·
Reading time: 7 min
Get more The El Paso stories like this
Free weekly briefing covering business and other local news. Curated by our editorial team. No spam.
By subscribing you agree to our privacy policy . Unsubscribe anytime.
Frequently asked about this story
What is this story about? By Anna Cooban, CNN London (CNN) — The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a $220 billion pharmaceutical company. It was day two of two. In a few hours’ time, the ...
When was this published? This article was first published on July 21, 2026 by KVIA ABC-7 and curated for The El Paso readers.
Who reported this story? This story was reported by CNN Newsource at KVIA ABC-7. To learn more about how The El Paso selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more business coverage from The El Paso, or browse our daily briefing and topic hubs .
← Back to all news
More business →
Today’s briefing
Subscribe to newsletter